Palatin, King terminate sublicense of Palatin, Competitive Technologies patents

By E. Janene Geiss

Philadelphia, Dec. 23 - Palatin Technologies, Inc. and King Pharmaceuticals, Inc. amended the collaborative development and marketing agreement signed in August, terminating King's sublicense of patents under a license agreement between Palatin and Competitive Technologies, Inc., according to an 8-K filing with the Securities and Exchange Commission.

Palatin and King said they concluded the sublicense was not necessary or useful for the development, manufacture, sale or other commercialization of PT-141, a nasally administered peptide in clinical development for the treatment of both male and female sexual dysfunction, the filing said.

Palatin is a Cranbury, N.J., biopharmaceutical company focused on discovering and developing melanocortin (MC)-based therapeutics.

King is a pharmaceutical company based in Bristol, Tenn.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.